Jointly established QIAGEN (Suzhou) Translational Medicine Co., Ltd with German QIAGEN N.V., the first domestic R&D enterprise on translational medicine, focusing on biomarkers and companion diagnostics.

Capacity Building：
· Established the nucleic acid detection platform and R&D laboratory of 1700m2
Honors：
The Comprehensive Pilot Enterprise of Modern Service Industry by the Ministry of Commerce – the Service Industry of Supporting Technology Research & development
· The Small and Medium-Sized Science & Technology Enterprises of Jiangsu Province
· The Private Technology Enterprise of Jiangsu Province

Capacity Building：
· Introduction of strategic investors: Simcere Pharma and Shanghai Anjie Medical Equipment Co., Ltd.
· Established the protein detection platform
· Started the research and development of IVD products
Honors：
· ISO9001 Quality Certification
· The Leading Talent in Science and Technology Entrepreneurship of "Jinji Lake Double-Hundred Talents" in Suzhou Industrial Park
· The High-skilled Leading Talent of "Jinji Lake Double Hundred Talents" in Suzhou Industrial Park
· The 3rd Innovation and Entrepreneurship "Winning Award" in Jiangsu, China
Strategic Partners：10+ pharmaceutical partners，e.g. Zai Lab, Innovent Bio and Sanofi.

Capacity Building：
· Established biomarker detection and R&D capabilities based on nucleic acid, protein and pathology platforms
· More than twenty research projects, with one invention patent, one utility model patent and two software copyrights
Honor：
· The National High-Tech Enterprise
· The Excellent Enterprise in the 4th Jiangsu Science and Technology Entrepreneurship Competition
· The Excellent Enterprise of the 5th China Innovation and Entrepreneurship Competition
· The Leading Talents in Science and Technology Entrepreneurship of the "Double-Creation Program" of Jiangsu Province
Strategic Partners：15 pharmaceutical partners, e.g. Suzhou Institute of Systems Medicine and Yingqiu Bio

Capacity Building：
· 1.75 Billion financing of Series A from professional financial investors：Qiming Ventures, Quanchuang Capital and New Horizon Capital
· Comprehensive commercial operation, empowering pharmaceutical companies to develop innovative drugs and companion diagnostic products
· Established NGS and Bioinformatics platforms, 5 software copyrights
Honors：
· CNAS & ISO17025 Certifications
· "Excellent Enterprise in Jiangsu Province" and "Excellent Entrepreneur in Jiangsu Province"
· National High-level Certificate for Overseas Talent
Industry Associations：
· Set up the Precision Medicine and Companion Diagnosis Professional Committee of the Chinese Society of Bioengineering, as one of the initiators.
· Vice Chairman of the 7th Council of Jiangsu Biotechnology Association, upon special invitation
Strategic Partners：
· 30 pharmaceutical partners
· Built the research and development center of nucleic acid sample library, collaborating with Soochow University and the First Affiliated Hospital of Soochow University

Capacity Building：
· Operation of two GMP production lines and storage rooms of 1700m2, based on nucleic acid and protein
· Declaration and filing on 20 ClassⅠIVD products
Honors：
· TÜV ISO13485 Quality Certification
· CAP Certification
· Multiple NCCL Inter-Laboratory Quality Assessments
· Distinguished Expert for Entrepreneurial Talents under the National "Thousand Talents Program"
· Innovative Leading Talents of Jiangsu Province's "Double Entrepreneurship Program"
· The Enterprise Growth Award of BioBay in Suzhou Industrial Park
· The Most Promising Enterprise of Overseas Talents, The Outstanding Enterprise of Keith Biotechnology in 2018
· Top 100 Chinese Pharmaceutical Enterprises in 2018
· The Leading Enterprise Award of Most Innovative Solutions on Precision Medicine;
· The Excellent Enterprise of Companion Diagnostic Solutions
· Top 10 Recommended Brands of Asia Pacific Precision Medicine Alliance for Tumor Immunotherapy Accompanied Genetic Testings
Strategic Partners：
· 60 pharmaceutical and hospital partners, e.g. China-Japan Friendship Hospital, CST, BGI, Abcam, Bio-Tech, Yi'an Jishi

Officially name changed from“QIAGEN (Suzhou) Translational Medicine Research Co., Ltd” to “MEDx Translational Medicine Research (Suzhou) Co., Ltd”
Capacity Building：
· Operation of clinical testing centers on nucleic acid, protein, cell and pathology platforms , with space of 1,700 m2
· Established the biomarker detection capabilities on flow cytometry platform, for new drug development
· Obtained 2 software copyrights
· Officially launched the clinical trial of first self-developed companion diagnostic product
· Launched the China Blueprint Program of PDL-1 testing
· Obtained the business licenses for both Class III and Class II medical devices
Strategic partners：
· Signed the strategic partnership with GoPath Laboratories in the United States to support clents in both China and US
· Total of 100 pharmaceutical partners, e.g. Junshi Bio, Dimai Bio, Chuangsheng Group
Honors：
· The Leading Talent in Suzhou Innovation and Entrepreneurship Program
· The Leading Talent of Science and Technology Innovation in Suzhou Industrial Park
· The Excellence Award in China Innovation and Entrepreneurship Competition of Medical Devices
· The Innovation Breakthrough Enterprise in Bio-industry
· The Enterprise in Park Gazelle Cultivation Program of Suzhou Industrial Park
· The Research Center of Suzhou Enterprise Engineering Technology

Capacity Building：
· $5.5 Billion Series B financing from professional investors, e.g. Qiming Venture Capital, Quanchuang Capital, Sinopharm Capital, Qingsong Capital and Borun Capital
· Acquired Greenikon (Shanghai) Medical Laboratory
· Obtained 2 software copyrights
· Accumulated more than 60 R&D projects, developed more than 50 kinds of protein and antibody raw materials, and started the registration plan for 6 self-developed Class III products
· Two CE-certified products: MSI Detection Kit, c-MET Exon-14 Skipping Mutation Detection Kit
Strategic Partners：total of 150 pharmaceutical partners， e.g. Henlius, Reindeer Medical
Honors：
· The Key Enterprise in To-Be-Listed Nursery Project of Suzhou Industrial Park
· The Foreign Investment R&D Center of Jiangsu Province
· The Technology Research Center of Cancer Precision Diagnosis Engineering in Jiangsu Province
· The Enterprise in Park Gazelle Cultivation Program of Suzhou Industrial Park
· Suzhou Unicorn Cultivation Enterprise

Capacity Building：
The Class-III product (trade name: Mai Jie Kang) approved by NMPA, as the first-in-China for JAK2-V617F detection
· 3 invention patents; 1 utility model patent
· Started the clinical trials of four independent research and development projects;
· Officially launched the clinical trial of first co-developed companion diagnostic product with pharmaceutical company;
· Established and initiated multiple development projects of companion diagnostic product with pharmaceutical companies
· New 500㎡ office space in use
Honors：
· The Pilot Enterprise of Integrated Yangtze River Delta, for Mutual Recognition of Risk Assessment Results of Special Items as the first batch
· Strategic Partners：Total of 200 pharmaceutical Parrtners, e.g. Spring Proswell, Xinyi Bio and Xuzhenda Bio